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Abstract
Background: Parvovirus B19 is the causative agent for erythema infectiosum, and also as a potentially life-
threatening infectious agent, it is mainly presented in high erythrocyte turnover patients. Sickle cell disease (SCD) is
an inherited monogenic hematological disorder resulting from the mutations in the hemoglobin β-chain gene.
Thalassemia is a hereditary hematological syndrome that happens in consequence of deficiencies in the production
of one or more globin chains. We summarize current knowledge about the prevalence rates of the parvovirus B19
infection in sickle cell anemia and thalassemia patients.
Methods: Several online databases were searched including, Scopus, EMBASE, Web of Science, Google Scholar, and
PubMed, which were performed amidst 2009–2019 by using distinct keywords: “Thalassemia,” “Parvovirus,” “Anemia,
” “Sickle cell anemia,” “parvoviridae,” “parvoviridae infection,” and “parvovirus B19.”
Results: Search results indicated 4 and 7 studies for the prevalence of the parvovirus B19 in β-thalassemia and SCD,
respectively. Among the β-thalassemia patients, the B19V seroprevalence for IgG and IgM were ranged from 18.2–
81% and 14.5–41.1%, respectively; meanwhile, B19V DNA positively results was 4–15.3%. Moreover, in the SCD
group, the extent of B19V IgG was varied from 37.6 to 65.9% and that of IgM was in a range of 2.9–30%, and the
DNA detection rate was 4–54%.
Conclusion: B19V seroprevalence changes in several conditions including, different epidemiological features, socio-
economic status, and overpopulation. Age can expand the incidence of anti-B19V IgG/IgM in SCD and beta-
thalassemia patients. Reinfection and diverse genotypes are relevant factors in the seroprevalence of B19v. The
patients’ immunological-hematological station and higher abundance of transfusions can affect the B19V
seroprevalence in SCD and beta-thalassemia group. Further investigations in this field could be suggested to better
understand the virus distribution in this susceptible population of patients.
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Introduction
The Parvoviridae family comprises two subfamilies
named Densovirinae and Parvovirinae; the latter afflicts
vertebrates, and the Erythrovirus genus, and parvovirus
B19 are its significant members [1]. The human parvo-
virus B19 is a small, linear, and single-stranded DNA
virus. The unexpected discovery of this virus was first
reported by Cossart et al. in 1975; it was found when the
donor sera were being tested for hepatitis B virus [2, 3].
It is mentioned that respiratory droplets are the means
for the transmission of the B19 virus, and close contacts
like household contact are also the other possible ways
[4, 5]. B19 can pass through the placenta and infect the
baby. Moreover, it is likely to be transmitted through
blood transfusions [6, 7].
Sickle cell disease (SCD) is an inherited monogenic
hematological disorder. Homozygous missense muta-
tions in the hemoglobin β-chain gene lead to the gener-
ation of sickle hemoglobin (HbS), and it is also
responsible for chronic damage to various organs [8, 9].
These mutations lead to thymine and glutamic acid sub-
stitution to adenine and valine, respectively [10]. In hyp-
oxemia condition, HbS reduces the flexibility of RBCs
(red blood cells) [11]. As a result, these fragile RBCs will
increase the hemolysis and lead to chronic anemia [9].
Furthermore, sickled erythrocytes disrupt the blood
flow in small capillaries and lead to a variety of disorders
[11]. Thalassemia is a hereditary hematological syn-
drome with deficits in the production of one or more
globin chains. The clinical characterizations are diverse,
ranging from hypochromia and microcytosis to
hemolytic anemia. The absence or reduction of β-globin
chains happens in β-thalassemia patients [12, 13]. Al-
though major β-thalassemia patients need regular blood
transfusions, it might cause a higher risk for B19 infec-
tion through blood transfusions [14–16]. Furthermore,
B19 is thought to be a potentially life-threatening infec-
tious agent in patients with high erythrocyte turnover
[17]. By and large, this paper explores the prevalence
rates of parvovirus B19 infection in sickle cell anemia
and thalassemia patients based on the study inclusion
criteria.
Methods
Study design and search strategy
This systematic review was carried out based on the cri-
teria drafted in the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analysis (PRISMA) statement
[18]. The PRISMA checklist was completed in all steps
of this research. We did not register the study protocol
before the initiation of the study.
In the current study, a literature search was performed
in the English language from 1 January 2009 until 2019.
The search process was performed in electronic
databases, such as PubMed, Scopus, Web of Science,
and Embase. For the search processing in the current
study according to medical subject headings (MeSH),
the following keywords were used “Thalassemia,”
“Parvovirus,” “Anemia,” “Sickle Cell anemia,” “parvoviri-
dae,” “parvoviridae infection,” “parvovirus B19.” The re-
ports were reviewed and managed with EndNote X8
(Thomson Reuters). The search was implemented by
two independent researchers, and a third researcher
checked the findings (Fig. 1).
Inclusion and exclusion criteria
The conducted search results were imported in EndNote
Version X8 (Thomson Reuters), and the duplicate stud-
ies were removed. The screening was done according to
the title and the abstract of articles, and finally, the full-
text was assessed. The administered inclusion criteria
were as follows: (1) investigations in cross-sectional, co-
hort, and case-series design that monitored the B19 in-
fection in sickle cell anemia and β-thalassemia patients
(2) articles published in English language and between
2009 and 2019 and (3) observational studies were also
included. All included articles met the inclusion criteria.
Absence of significance and relevance of the data in the
articles and the ones that did not meet the eligibility cri-
teria were excluded. The non-representativeness of the
study population and those studies utilized of non-
standard estimation devices were also removed. More-
over, case reports and case series with no significant
sample size were excluded. These review articles (the lit-
erature reviews which were screened for relevant data),
congress abstracts, and letters to the editor were
excluded.
Qualitative assessment
All the eligible studies entered were evaluated for risk of
bias utilizing the Critical Appraisal Skills Programme
(CASP) checklist. The risk of bias in particular studies
was ranked as low, moderate, and high. Studies with a
high risk of bias were omitted.
Data extraction
To prevent bias, two independent reviewers double-
screened the final search results based on titles, ab-
stracts, and full texts of articles according to inclusion
and exclusion criteria. The third expert researcher solved
the conflicts. The data of all included studies were sum-
marized by using a data extraction sheet in EXCEL soft-
ware, which covered the first author’s name, country,
publication year, thalassemia or sickle cell disease pa-
tients, thalassemia type, sample size, age, sex, IgG, and
IgM prevalence, B19 virus genotypes, serological (ELIS
A), and molecular (PCR) diagnostic methods and study
design.
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Results
In this literature review, the results of eleven different
studies that assessed the parvovirus B19 infection in two
different groups of patients were compiled. The con-
ducted search result is illustrated in Fig. 1. Also, four
studies evaluated general factors in patients with thalas-
semia. Six studies focused on patients with SCD. One
study assessed parvovirus in patients with either thalas-
semia or sickle cell disease. Overall, 334 thalassemia and
1016 SCD patients were identified in these articles. The
results were summarized in Tables 1 and 2. The follow-
ing studies were published between 2011 and 2017.
Parvovirus B19 estimated prevalence in beta-thalassemia
major patients
Among four studies focused on the prevalence of the
parvovirus B19 in β-thalassemia, beta-thalassemia patients’
lowest mean age was 6.2 ± 13.25 years in Egypt, and the
highest mean age degree was 30.4 years in Iran. However,
considering the mean age result between beta-thalassemia
patients, most cases were in childhood. The B19V sero-
prevalence is dependent on age, and it rises steadily from
early childhood to the elderly. Presumably, some of the in-
cluded studies in our review, from the India Province,
showed an association between the prevalence of parvo-
virus B19 infection and several factors such as childhood
age, poor socio-economic conditions, and overpopulation.
Taking these four studies into account, it is note-
worthy that in 184 patients, the anti-B19V IgG in β-
thalassemia patients ranged from 18.2 to 81%. The result
of three different studies indicates that the anti-B19V
IgM in β-thalassemia patients ranged from 14.5 to 41.1%
in 145. Furthermore, the B19V DNA predominance rate
was shown to be 4–15.3% in 189 patients.
Fig. 1 Conducted study search flowchart
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Parvovirus B19 prevalence in SCD patients
Seven different studies focused on the prevalence of the
parvovirus B19 in SCD were taken into consideration.
The mean age of SCD patients showed different ranges
in economically developing countries such as Nigeria
(16.9 ± 0.7 years) and rich countries like Saudi Arabia,
i.e., 28 years.
Anti-B19V IgM
In six different studies, the anti-B19V IgG levels in SCD
patients’ sera was varied from 37.6 to 65.9% in 948 pa-
tients. Furthermore, in five different studies, it was indi-
cated that the anti-B19V IgM in SCD patients ranged
from 2.9 to 30% in 542 patients. The parvovirus B19
DNA predominance rate was 4–54% in 455 patients in
four separate studies.
Discussion
Human parvovirus B19, the causative agent for ery-
thema infectiosum (fifth disease), has a tropism for
erythroid progenitor cells, and in consequence, it can
temporarily suppress erythropoiesis in bone marrow
[29, 30]. In SCD and Thalassemia patients, the parvo-
virus B19 infection makes more severe conditions,
known as a transient aplastic crisis [20, 31]. The β-
thalassemia patients have a higher risk for the infec-
tion of the parvovirus B19 due to the necessity of
multiple blood transfusions throughout their life [32].
In the study carried out by Kishore et al. in northern
India, the frequency of parvovirus B19 infection was
assessed in 90 major β-thalassemia patients with a
hyper-transfusion regimen who had 10–360 units of
blood transfusion in their whole life and 32 controls.
The results of the study indicated that the age range
of participants was 2–18 years, and 61% were males.
In house ELISA for VP-1 and VP-2 was used to de-
tect anti-B19 IgM/IgG antibodies; it revealed that the
parvovirus IgG and IgM prevalence in major β-
thalassemia patients were 81% and 41%, respectively.
It was also suggested that the seroprevalence of the
parvovirus infection and the numbers of blood trans-
fusion times are directly proportional [21]. Further-
more, Arabzadeh and colleagues investigated blood
samples of 150 β-thalassemia major patients (75
males, 75 females) by real-time PCR to determine the
prevalence of parvovirus B19 DNA. This study's re-
sults indicate that 4% of enrolled patients were posi-
tive for parvovirus B19 DNA, and half of these
participants were aged 26–30 years and others were
31–35 [22].
The academic community has extensively explored the
titer of B19 IgG and IgM in SCD patients. Having said
that, Ayolabi et al. investigated the level of parvovirus
B19 IgM antibody in 68 SCD patients and 25 control
samples by ELISA. Anti-parvovirus B19 IgM was de-
tected in 15% of SCD patients. Also, Obeid assessed the
parvovirus B19 antibody and DNA in 138 SCD patients.
Obeid’s study showed that the parvovirus B19 IgG and
IgM prevalences are 37.6% and 2.89%, respectively.
Moreover, the parvovirus B19 DNA was detected in all
IgM positive patients [24]. In another study in Egypt,
Makhlouf et al. assessed the serological and molecular
prevalence of the parvovirus B19 in 100 SCD patients
and 60 controls. The results revealed that 30% of SCD
patients were positive for the parvovirus B19 IgM and
DNA, while 24% had positive IgG and DNA by nested-
PCR [25].
Parvovirus B19 seroprevalence alters in various coun-
tries due to different causes. Hankins et al. reported that
the incidence of parvovirus B19- specific antibody re-
sponses in pediatric SCD cases is expanded with age, as
suspected due to an increased likelihood of parvovirus
B19 exposure [26]. In the Arabzadeh et al. study,
parvovirus-infected patients’ mean age was 30.4 years
[22]. The epidemiological aspects can affect the B19V
seroprevalence in different groups of patients. Although
this epidemiological division shows the immune re-
sponse to B19V, it confirms the risen viral dissemination
between elderly patients with SCD [20]. Reinfection is
another relevant factor in maintaining B19V seropreva-
lence [20]. The different genotypes can influence
antibody-positive and DNA-positive samples in different
countries of Europe and Africa [24]. Kishore et al. re-
ported no significant associations between parvovirus
prevalence and thalassemia patients' age and gender.
They mentioned that the B19V seroprevalence was
raised to the low socio-economic status or a higher
abundance of transfusions received by these patients
[21]. Prior investigations queried the factors impacting
on its seroprevalence. Ghwass et al. stated that the dif-
ferences in B19V seroprevalence in different areas are
dependant on the climate, variable socio-economic sta-
tus, overpopulation, geographical, and the variety in the
immunological-hematological status of patients [19].
The differences in all these studies could be due to the
differences in the sample size and geographical distribu-
tion. This study was conducted as a preliminary study
that could be useful for further systematic review and
meta-analysis by narrowing it in this field of study. It
could be used entirely as a reminder for more protective
actions about parvovirus B19 transmission in susceptible
patients. The drawback of this framework was the ab-
sence of quantitative analysis
Conclusion
Parvovirus B19 seroprevalence changes in several con-
ditions in different countries and communities. The
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age can expand the incidence of anti-B19V IgG/IgM
in SCD and beta-thalassemia patients. Also, the epi-
demiological features can affect the B19V seropreva-
lence in groups of patients. Reinfection and diverse
genotypes are additional relevant criteria in maintain-
ing B19V seroprevalence and DNA-positively results.
However, the differences in B19V seroprevalence in
different areas are dependent on the socio-economic
situation and overpopulation. Additionally, the differ-
ence in patients' immunological-hematological condi-
tion and higher abundance of transfusions received by
patients are other factors that affect the B19V sero-
prevalence. Further investigations in the field of SCD
or thalassemia and B19V infection is suggested to
gain a better understanding of the virus distribution
in susceptible populations.
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